Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673862 | 1.00 | USP2 (0.45) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| SCHEMBL19981311 | 1.00 | USP2 (0.45) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| SCHEMBL587730 | 1.00 | USP2 (0.45) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| SCHEMBL598942 | 1.00 | USP2 (0.45) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| SCHEMBL28890368 | 0.92 | USP2 (0.44) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| SCHEMBL7420375 | 0.87 | SLC7A5 (0.50) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| SCHEMBL755924 | 0.87 | SLC7A5 (0.50) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| SCHEMBL1168875 | 0.87 | SLC7A5 (0.50) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| SCHEMBL28319949 | 0.85 | SLC7A5 (0.48) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| SCHEMBL28319951 | 0.85 | SLC7A5 (0.48) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | USP2 3994/4885SLCO1B1 1599/4885SLC7A5 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.